Doxorubicin (A) followed by docetaxel (T) versus doxorubicin plus docetaxel (AT) in the adjuvant treatment of breast cancer (BC)

被引：2
|
作者：
Di Leo, A
Crown, J
Nogaret, LM
Duffy, K
Bartholomeus, S
Dolci, S
Rowan, S
O'Higgins, N
Riva, A
Piccart, MJ
机构：
[1] Inst Jules Bordet, B-1000 Brussels, Belgium
[2] St Vincents Hosp, Dublin 4, Ireland
[3] Rhone Poulenc Rorer, Paris, France
来源：
EUROPEAN JOURNAL OF CANCER | 1998年 / 34卷
关键词：
D O I：
10.1016/S0959-8049(98)80153-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
166
引用
收藏
页码：S41 / S41
页数：1
相关论文
共 50 条
  • [31] Neoadjuvant Doxorubicin followed sequentially by Cisplatin-Docetaxel in locally advanced breast cancer
    不详
    [J]. BREAST, 2005, 14 : S42 - S42
  • [32] Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study
    Lambert-Falls, Rosemary
    Modugno, Susan
    [J]. CLINICAL BREAST CANCER, 2007, 7 (09) : 697 - 704
  • [33] Cost-Effectiveness Analysis of Adjuvant Therapy for Operable Breast Cancer from a Chinese Perspective Doxorubicin plus Cyclophosphamide versus Docetaxel plus Cyclophosphamide
    Peng Liubao
    Wan Xiaomin
    Tan Chongqing
    Karnon, Jon
    Chen Gannong
    Li Jianhe
    Cui Wei
    Luo Xia
    Cao Junhua
    [J]. PHARMACOECONOMICS, 2009, 27 (10) : 873 - 886
  • [34] Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer
    Chan, S
    Friedrichs, K
    Noel, D
    Pintér, T
    Van Belle, S
    Vorobiof, D
    Duarte, R
    Gil, MG
    Bodrogi, I
    Murray, E
    Yelle, L
    von Minckwitz, G
    Korec, S
    Simmonds, P
    Buzzi, F
    Mancha, RG
    Richardson, G
    Walpole, E
    Ronzoni, M
    Murawsky, M
    Alakl, M
    Riva, A
    Crown, J
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) : 2341 - 2354
  • [35] Primary systemic therapy using docetaxel/cyclophosphamide/bevacizumab (TCB) followed by doxorubicin (A) in operable or locally advanced breast cancer (BC)
    Makhoul, I
    Klimberg, S.
    Henri-Tillmen, R.
    Westbrook, K.
    Hutchins, L.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S224 - S225
  • [36] Primary systemic therapy using docetaxel/cyclophosphamide/bevacizumab (TCB) followed by doxorubicin (A) in operable or locally advanced breast cancer (BC)
    Makhoul, I.
    Klimberg, S.
    Henry-Tillman, R.
    Westbrook, K.
    Korourian, S.
    Siegel, E.
    Hutchins, L.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2008, 109 (03) : 592 - 593
  • [37] Docetaxel (Taxotere) plus doxorubicin-based combinations: The evidence of activity in breast cancer
    Nabholtz, JM
    [J]. SEMINARS IN ONCOLOGY, 1999, 26 (03) : 7 - 13
  • [38] Benefit of neoadjuvant capecitabine plus epirubicin plus cyclophosphamide (CEX) versus 5-FU + epirubicin plus cyclophosphamide (FEC) for operable breast cancer (BC) followed by adjuvant docetaxel (T)
    Berton-Rigaud, D.
    Roche, H.
    Penault-Llorca, F.
    Tubiana-Mathieu, N.
    Ferrero, J.
    Coudert, B.
    Milano, G. A.
    Mousseau, M.
    Homokos, H.
    Fumoleau, P.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [39] Combinational Treatment of Doxorubicin With Neoadjuvant Docetaxel for Different Subtypes of Patients With Breast Cancer
    Wang, Ling-Cheng
    Wang, Ling-Sheng
    Li, Ai-Xia
    Shi, Zhen-Zong
    Li, Ya-Qiong
    Huang, Wei
    Chen, Shi-Man
    Han, Fei
    Zhu, De-Qiang
    [J]. TECHNOLOGY IN CANCER RESEARCH & TREATMENT, 2020, 19
  • [40] Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)
    Sang Gyu Lee
    Young Geon Jee
    Hyun Chul Chung
    Sung-Bae Kim
    Jungsil Ro
    Young-Hyuck Im
    Seock-Ah Im
    Jae Hong Seo
    [J]. Breast Cancer Research and Treatment, 2009, 114 : 589 - 595
12345